Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04627428
PHASE1/PHASE2

Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

Sponsor: Luxa Biotechnology, LLC

View on ClinicalTrials.gov

Summary

The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.

Official title: A Phase1/2a, Open-Label Study to Evaluate the Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD)

Key Details

Gender

All

Age Range

55 Years - Any

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2022-04-05

Completion Date

2026-12-01

Last Updated

2025-10-15

Healthy Volunteers

No

Interventions

BIOLOGICAL

RPESC-RPE-4W

RPESC-RPE-4W

Locations (3)

Retina Vitreous Associates Medical Group

Beverly Hills, California, United States

Spencer Center for Vision Research

Palo Alto, California, United States

University of Michigan Kellogg Eye Center

Ann Arbor, Michigan, United States